Compare Novartis AG (NVS) vs Okta, Inc. (OKTA) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Okta (OKTA) trades at $167.60, down 1.76% on the day, but remains up 94% year-to-date driven by strong earnings beats and AI-driven demand for cybersecurity. The stock exhibits a bullish technical trend, with moving averages signaling strength and key support at $166. Fundamentally, revenue grew to $2.61 billion in 2025 with a net income margin turning positive at 1.07%, while valuation ratios like P/E of 100.96 reflect high growth expectations. Recent news highlights AI security offerings boosting investor confidence.

Outlook is positive with a consensus price target of $181.61, indicating 8% upside, supported by 75% analyst buy ratings. Opportunities include expanding AI identity governance and enterprise adoption, but risks involve intense competition from CrowdStrike and Microsoft, high valuation multiples, and integration challenges. Net cash flow turned positive in 2025, though debt-to-asset ratio improved to 9.09%.